Publications by authors named "P Desenzani"
Article Synopsis
- - From clinical trials and observational studies, oral semaglutide has emerged as the top option for second-line oral treatment in type 2 diabetes management, highlighting its effectiveness in both controlled and real-world settings.
- - An expert panel in Italy discussed the practical challenges of using oral semaglutide in everyday clinical care, covering topics like its effectiveness, flexible dosing, communication with patients, and handling side effects.
- - The panel also analyzed available data, debated fixed versus flexible dosing schedules, and offered recommendations to help clinicians effectively prescribe and monitor patients using oral semaglutide.
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor and semaglutide, a glucagon-like peptide 1 receptor agonist, have both demonstrated efficacy in glycemic control, reducing blood pressure, body weight, risk of renal and heart failure in type 2 diabetes mellitus. In this observational, real-world, study we aimed to investigate the efficacy of the combination therapy with those two agents over glycemic control. We thus obtained the data of 1335 patients with type 2 diabetes followed by 11 Diabetes centers in Lombardia, Italy.
View Article and Find Full Text PDFDapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to renal failure, of hospitalization for heart failure and of cardiovascular death. We aim to investigate the acute effect of Dapagliflozin on kidney function in the common clinical practice in T2D. This is a study including 1402 patients with T2D recruited from 11 centers in Lombardia, Italy, who were evaluated at baseline and after 6 months of treatment with Dapagliflozin 10 mg per day.
View Article and Find Full Text PDFShort-Term Consequences of SARS-CoV-2-Related Pneumonia: A Follow Up Study.
High Blood Press Cardiovasc Prev
July 2021
Article Synopsis
- The study examined the short-term effects of SARS-CoV-2 pneumonia in 94 patients at Montichiari Hospital, highlighting that one-quarter of them showed signs of pulmonary fibrosis four months post-discharge.
- About half of the patients reported ongoing symptoms such as fatigue and anxiety, indicating significant quality of life impacts.
- The research also found that certain prognostic indices could effectively predict the severity of lung involvement, suggesting that some measurements may help identify patients at greater risk for complications.
The aim of the present study was to simultaneously assess several potential predictors of outcome (co-morbidity, previous and in-hospital treatment, radiologic Brixia score) in patients with COVID-19. This retrospective cohort study included 258 consecutive patients with confirmed COVID-19 admitted to a medical ward at Montichiari Hospital, Brescia, Italy from February 28th to April 30rd, 2020. Patients had SARS-CoV-2 related pneumonia with respiratory failure, and were treated with hydroxychloroquine and lopinavir plus ritonavir.
View Article and Find Full Text PDF